nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—Costochondritis—Varenicline—nicotine dependence	0.103	0.13	CcSEcCtD
Etoricoxib—Coronary artery disease—Varenicline—nicotine dependence	0.0273	0.0346	CcSEcCtD
Etoricoxib—Aphthous stomatitis—Varenicline—nicotine dependence	0.023	0.0291	CcSEcCtD
Etoricoxib—Sinus congestion—Varenicline—nicotine dependence	0.0217	0.0275	CcSEcCtD
Etoricoxib—Transient ischaemic attack—Varenicline—nicotine dependence	0.0214	0.0271	CcSEcCtD
Etoricoxib—Platelet count decreased—Varenicline—nicotine dependence	0.0182	0.023	CcSEcCtD
Etoricoxib—Toothache—Varenicline—nicotine dependence	0.0178	0.0225	CcSEcCtD
Etoricoxib—Cyst—Varenicline—nicotine dependence	0.0162	0.0204	CcSEcCtD
Etoricoxib—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0155	0.0741	CbGpPWpGaD
Etoricoxib—Fungal infection—Varenicline—nicotine dependence	0.014	0.0177	CcSEcCtD
Etoricoxib—Glycosuria—Varenicline—nicotine dependence	0.0133	0.0169	CcSEcCtD
Etoricoxib—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.012	0.0572	CbGpPWpGaD
Etoricoxib—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.012	0.0151	CcSEcCtD
Etoricoxib—Nocturia—Varenicline—nicotine dependence	0.0116	0.0147	CcSEcCtD
Etoricoxib—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.011	0.0526	CbGpPWpGaD
Etoricoxib—Musculoskeletal pain—Varenicline—nicotine dependence	0.0109	0.0138	CcSEcCtD
Etoricoxib—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0109	0.0522	CbGpPWpGaD
Etoricoxib—Blood pressure increased—Varenicline—nicotine dependence	0.0108	0.0137	CcSEcCtD
Etoricoxib—Hyperkalaemia—Varenicline—nicotine dependence	0.0106	0.0134	CcSEcCtD
Etoricoxib—Mouth ulceration—Varenicline—nicotine dependence	0.00977	0.0124	CcSEcCtD
Etoricoxib—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.00962	0.046	CbGpPWpGaD
Etoricoxib—Diabetes mellitus—Varenicline—nicotine dependence	0.00901	0.0114	CcSEcCtD
Etoricoxib—Eczema—Varenicline—nicotine dependence	0.00872	0.011	CcSEcCtD
Etoricoxib—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00859	0.0411	CbGpPWpGaD
Etoricoxib—Injury—Varenicline—nicotine dependence	0.00853	0.0108	CcSEcCtD
Etoricoxib—Visual disturbance—Varenicline—nicotine dependence	0.00827	0.0105	CcSEcCtD
Etoricoxib—Atrial fibrillation—Varenicline—nicotine dependence	0.00827	0.0105	CcSEcCtD
Etoricoxib—Thirst—Varenicline—nicotine dependence	0.00824	0.0104	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Varenicline—nicotine dependence	0.008	0.0101	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00784	0.00992	CcSEcCtD
Etoricoxib—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00742	0.0355	CbGpPWpGaD
Etoricoxib—Breast disorder—Varenicline—nicotine dependence	0.00709	0.00896	CcSEcCtD
Etoricoxib—Cramp muscle—Varenicline—nicotine dependence	0.00706	0.00893	CcSEcCtD
Etoricoxib—Gastritis—Varenicline—nicotine dependence	0.00694	0.00878	CcSEcCtD
Etoricoxib—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00683	0.0326	CbGpPWpGaD
Etoricoxib—Abdominal distension—Varenicline—nicotine dependence	0.00682	0.00863	CcSEcCtD
Etoricoxib—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00677	0.0323	CbGpPWpGaD
Etoricoxib—Angina pectoris—Varenicline—nicotine dependence	0.0066	0.00835	CcSEcCtD
Etoricoxib—Bronchitis—Varenicline—nicotine dependence	0.00652	0.00824	CcSEcCtD
Etoricoxib—Abdominal discomfort—Varenicline—nicotine dependence	0.0065	0.00822	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Varenicline—nicotine dependence	0.00619	0.00782	CcSEcCtD
Etoricoxib—Weight increased—Varenicline—nicotine dependence	0.00617	0.0078	CcSEcCtD
Etoricoxib—Hyperglycaemia—Varenicline—nicotine dependence	0.00611	0.00773	CcSEcCtD
Etoricoxib—Infestation—Varenicline—nicotine dependence	0.00604	0.00764	CcSEcCtD
Etoricoxib—Infestation NOS—Varenicline—nicotine dependence	0.00604	0.00764	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00599	0.00758	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Varenicline—nicotine dependence	0.00596	0.00753	CcSEcCtD
Etoricoxib—Myocardial infarction—Varenicline—nicotine dependence	0.00592	0.00749	CcSEcCtD
Etoricoxib—Stomatitis—Varenicline—nicotine dependence	0.00589	0.00745	CcSEcCtD
Etoricoxib—Conjunctivitis—Varenicline—nicotine dependence	0.00587	0.00743	CcSEcCtD
Etoricoxib—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00578	0.0276	CbGpPWpGaD
Etoricoxib—Hepatobiliary disease—Varenicline—nicotine dependence	0.00571	0.00723	CcSEcCtD
Etoricoxib—Epistaxis—Varenicline—nicotine dependence	0.0057	0.00721	CcSEcCtD
Etoricoxib—Sinusitis—Varenicline—nicotine dependence	0.00567	0.00717	CcSEcCtD
Etoricoxib—MAPK14—RAC1 signaling pathway—WASF2—nicotine dependence	0.00548	0.0262	CbGpPWpGaD
Etoricoxib—Hallucination—Varenicline—nicotine dependence	0.0054	0.00683	CcSEcCtD
Etoricoxib—Hypoaesthesia—Varenicline—nicotine dependence	0.0054	0.00683	CcSEcCtD
Etoricoxib—Urinary tract disorder—Varenicline—nicotine dependence	0.00536	0.00677	CcSEcCtD
Etoricoxib—Oedema peripheral—Varenicline—nicotine dependence	0.00534	0.00676	CcSEcCtD
Etoricoxib—Connective tissue disorder—Varenicline—nicotine dependence	0.00533	0.00674	CcSEcCtD
Etoricoxib—Urethral disorder—Varenicline—nicotine dependence	0.00532	0.00672	CcSEcCtD
Etoricoxib—MAPK14—RAC1 signaling pathway—WASF1—nicotine dependence	0.00525	0.0251	CbGpPWpGaD
Etoricoxib—Visual impairment—Varenicline—nicotine dependence	0.00523	0.00661	CcSEcCtD
Etoricoxib—Erythema multiforme—Varenicline—nicotine dependence	0.00513	0.00649	CcSEcCtD
Etoricoxib—Eye disorder—Varenicline—nicotine dependence	0.00507	0.00641	CcSEcCtD
Etoricoxib—Tinnitus—Varenicline—nicotine dependence	0.00506	0.0064	CcSEcCtD
Etoricoxib—Cardiac disorder—Varenicline—nicotine dependence	0.00503	0.00637	CcSEcCtD
Etoricoxib—Angiopathy—Varenicline—nicotine dependence	0.00492	0.00622	CcSEcCtD
Etoricoxib—Immune system disorder—Varenicline—nicotine dependence	0.0049	0.0062	CcSEcCtD
Etoricoxib—Mediastinal disorder—Varenicline—nicotine dependence	0.00489	0.00618	CcSEcCtD
Etoricoxib—Arrhythmia—Varenicline—nicotine dependence	0.00485	0.00613	CcSEcCtD
Etoricoxib—Mental disorder—Varenicline—nicotine dependence	0.00475	0.00601	CcSEcCtD
Etoricoxib—Erythema—Varenicline—nicotine dependence	0.00472	0.00597	CcSEcCtD
Etoricoxib—Malnutrition—Varenicline—nicotine dependence	0.00472	0.00597	CcSEcCtD
Etoricoxib—Flatulence—Varenicline—nicotine dependence	0.00465	0.00588	CcSEcCtD
Etoricoxib—Dysgeusia—Varenicline—nicotine dependence	0.00462	0.00585	CcSEcCtD
Etoricoxib—Muscle spasms—Varenicline—nicotine dependence	0.00454	0.00574	CcSEcCtD
Etoricoxib—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00446	0.0213	CbGpPWpGaD
Etoricoxib—Vision blurred—Varenicline—nicotine dependence	0.00445	0.00563	CcSEcCtD
Etoricoxib—Tremor—Varenicline—nicotine dependence	0.00442	0.00559	CcSEcCtD
Etoricoxib—Anaemia—Varenicline—nicotine dependence	0.00436	0.00552	CcSEcCtD
Etoricoxib—Agitation—Varenicline—nicotine dependence	0.00434	0.00549	CcSEcCtD
Etoricoxib—Angioedema—Varenicline—nicotine dependence	0.00431	0.00546	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—OPRM1—nicotine dependence	0.00423	0.0202	CbGpPWpGaD
Etoricoxib—Palpitations—Varenicline—nicotine dependence	0.00417	0.00528	CcSEcCtD
Etoricoxib—Cough—Varenicline—nicotine dependence	0.00412	0.00521	CcSEcCtD
Etoricoxib—Hypertension—Varenicline—nicotine dependence	0.00408	0.00516	CcSEcCtD
Etoricoxib—Arthralgia—Varenicline—nicotine dependence	0.00402	0.00508	CcSEcCtD
Etoricoxib—Chest pain—Varenicline—nicotine dependence	0.00402	0.00508	CcSEcCtD
Etoricoxib—Anxiety—Varenicline—nicotine dependence	0.00401	0.00507	CcSEcCtD
Etoricoxib—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00399	0.0191	CbGpPWpGaD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00399	0.00505	CcSEcCtD
Etoricoxib—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00394	0.0188	CbGpPWpGaD
Etoricoxib—Dry mouth—Varenicline—nicotine dependence	0.00393	0.00497	CcSEcCtD
Etoricoxib—Oedema—Varenicline—nicotine dependence	0.00385	0.00487	CcSEcCtD
Etoricoxib—Infection—Varenicline—nicotine dependence	0.00383	0.00484	CcSEcCtD
Etoricoxib—Shock—Varenicline—nicotine dependence	0.00379	0.00479	CcSEcCtD
Etoricoxib—Nervous system disorder—Varenicline—nicotine dependence	0.00378	0.00478	CcSEcCtD
Etoricoxib—Thrombocytopenia—Varenicline—nicotine dependence	0.00377	0.00477	CcSEcCtD
Etoricoxib—Skin disorder—Varenicline—nicotine dependence	0.00374	0.00473	CcSEcCtD
Etoricoxib—Anorexia—Varenicline—nicotine dependence	0.00367	0.00465	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00351	0.00444	CcSEcCtD
Etoricoxib—Insomnia—Varenicline—nicotine dependence	0.00349	0.00441	CcSEcCtD
Etoricoxib—Dyspnoea—Varenicline—nicotine dependence	0.00344	0.00434	CcSEcCtD
Etoricoxib—Somnolence—Varenicline—nicotine dependence	0.00343	0.00433	CcSEcCtD
Etoricoxib—Dyspepsia—Varenicline—nicotine dependence	0.00339	0.00429	CcSEcCtD
Etoricoxib—Decreased appetite—Varenicline—nicotine dependence	0.00335	0.00424	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00333	0.00421	CcSEcCtD
Etoricoxib—Fatigue—Varenicline—nicotine dependence	0.00332	0.0042	CcSEcCtD
Etoricoxib—Constipation—Varenicline—nicotine dependence	0.0033	0.00417	CcSEcCtD
Etoricoxib—Pain—Varenicline—nicotine dependence	0.0033	0.00417	CcSEcCtD
Etoricoxib—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00324	0.0155	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Varenicline—nicotine dependence	0.00318	0.00402	CcSEcCtD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.00317	0.0151	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00315	0.00399	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—OPRM1—nicotine dependence	0.00314	0.015	CbGpPWpGaD
Etoricoxib—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00308	0.0147	CbGpPWpGaD
Etoricoxib—Urticaria—Varenicline—nicotine dependence	0.00306	0.00387	CcSEcCtD
Etoricoxib—Abdominal pain—Varenicline—nicotine dependence	0.00305	0.00385	CcSEcCtD
Etoricoxib—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00304	0.0145	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.00304	0.0145	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—WASF2—nicotine dependence	0.00299	0.0143	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—WASF1—nicotine dependence	0.00287	0.0137	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Varenicline—nicotine dependence	0.00284	0.00359	CcSEcCtD
Etoricoxib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00283	0.0135	CbGpPWpGaD
Etoricoxib—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00281	0.0134	CbGpPWpGaD
Etoricoxib—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0028	0.0134	CbGpPWpGaD
Etoricoxib—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00277	0.0132	CbGpPWpGaD
Etoricoxib—Asthenia—Varenicline—nicotine dependence	0.00276	0.0035	CcSEcCtD
Etoricoxib—Pruritus—Varenicline—nicotine dependence	0.00273	0.00345	CcSEcCtD
Etoricoxib—Diarrhoea—Varenicline—nicotine dependence	0.00264	0.00333	CcSEcCtD
Etoricoxib—Dizziness—Varenicline—nicotine dependence	0.00255	0.00322	CcSEcCtD
Etoricoxib—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0025	0.0119	CbGpPWpGaD
Etoricoxib—Vomiting—Varenicline—nicotine dependence	0.00245	0.0031	CcSEcCtD
Etoricoxib—Rash—Varenicline—nicotine dependence	0.00243	0.00307	CcSEcCtD
Etoricoxib—Dermatitis—Varenicline—nicotine dependence	0.00243	0.00307	CcSEcCtD
Etoricoxib—Headache—Varenicline—nicotine dependence	0.00241	0.00305	CcSEcCtD
Etoricoxib—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0024	0.0115	CbGpPWpGaD
Etoricoxib—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00237	0.0113	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—FGD1—nicotine dependence	0.00232	0.0111	CbGpPWpGaD
Etoricoxib—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0023	0.011	CbGpPWpGaD
Etoricoxib—Nausea—Varenicline—nicotine dependence	0.00229	0.00289	CcSEcCtD
Etoricoxib—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00228	0.0109	CbGpPWpGaD
Etoricoxib—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00195	0.0093	CbGpPWpGaD
Etoricoxib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00185	0.00885	CbGpPWpGaD
Etoricoxib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00183	0.00874	CbGpPWpGaD
Etoricoxib—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00182	0.00872	CbGpPWpGaD
Etoricoxib—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.00172	0.00822	CbGpPWpGaD
Etoricoxib—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0017	0.00811	CbGpPWpGaD
Etoricoxib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0015	0.00718	CbGpPWpGaD
Etoricoxib—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00141	0.00673	CbGpPWpGaD
Etoricoxib—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00133	0.00634	CbGpPWpGaD
Etoricoxib—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00131	0.00625	CbGpPWpGaD
Etoricoxib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00129	0.00619	CbGpPWpGaD
Etoricoxib—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00128	0.00613	CbGpPWpGaD
Etoricoxib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00122	0.00583	CbGpPWpGaD
Etoricoxib—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00121	0.00578	CbGpPWpGaD
Etoricoxib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0012	0.00575	CbGpPWpGaD
Etoricoxib—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00119	0.0057	CbGpPWpGaD
Etoricoxib—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0011	0.00524	CbGpPWpGaD
Etoricoxib—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00103	0.00494	CbGpPWpGaD
Etoricoxib—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00102	0.00487	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—CCAR1—nicotine dependence	0.000976	0.00466	CbGpPWpGaD
Etoricoxib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000847	0.00405	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—WASF2—nicotine dependence	0.000823	0.00393	CbGpPWpGaD
Etoricoxib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000798	0.00381	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—WASF1—nicotine dependence	0.000789	0.00377	CbGpPWpGaD
Etoricoxib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000787	0.00376	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TAS2R16—nicotine dependence	0.000635	0.00303	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGD1—nicotine dependence	0.000498	0.00238	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—WASF2—nicotine dependence	0.000479	0.00229	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—WASF1—nicotine dependence	0.00046	0.0022	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKR1B10—nicotine dependence	0.00044	0.0021	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKR1B10—nicotine dependence	0.000401	0.00192	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CYP2A7—nicotine dependence	0.000312	0.00149	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—WASF2—nicotine dependence	0.00031	0.00148	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—WASF1—nicotine dependence	0.000297	0.00142	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000294	0.00141	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—OPRM1—nicotine dependence	0.000268	0.00128	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000227	0.00108	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000209	0.000997	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000207	0.000989	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—DRD2—nicotine dependence	0.000193	0.000924	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000177	0.000845	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000136	0.000652	CbGpPWpGaD
